Microbial Resistance CME
In 2011, the World Health Organization (WHO) reported that 63,000 patients die each year in US hospitals and 25,000 patients lose their lives annually in the European Union due to antibiotic-resistant infections. The annual estimated economic burden is US $2.1 billion in the European Union, US $34 billion in the United States, and US $2.453 billion globally.
Antimicrobial drug resistance (AMR or AMDR) is a multidimensional and systemic failure of the health, education, societal behavior, and medical policies and practices.
Four major challenges should be recognized and addressed by the world medical community.
- AMDR is extending beyond national boundaries, presenting a significant threat to health and increasing the costs of medical care.
- Collaboration among healthcare, pharmaceutical, agricultural, and consumer communities is a prerequisite to ward off this evolving pandemic.
- Adequate funding for proactive surveillance and development of new antimicrobial drugs and vaccines should be made available.
- Antibiotic drug stewardship, including education of stakeholders, implementation of hygiene practices, and responsible dispensing and use, are essential strategic elements of all preventive practices.
A continued professional education activity* jointly sponsored by the Center for the Study of International Medical Policies and Practices (CSIMPP), School of Public Policy, George Mason University and MedEDirect, LTD., in collaboration with the World Medical Association (WMA) and the International Society for Microbial Resistance (ISMR) has been developed. CME credits are also available free of charge through the MedEDirect at www.MedEDirect.org.
* This link includes updates to the materials and teaching power points.